GlassScriptPhysician profile
Marlin D Gill
NPI 1336251636
$8,081.43
in general payments reported to CMS, 2019-2025
40 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $1,066 · 2021: $1,742 · 2022: $1,341 · 2023: $1,086 · 2024: $971 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.97 | 2021-2025 | |
| Novo Nordisk INC | $991.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $607.72 | 2019-2022 | |
| Amarin Pharma, INC. | $602.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $538.42 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $474.21 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $416.71 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $376.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.76 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $155.07 | 2021-2025 | Kisunla, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $149.63 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.58 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $140.44 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $133.57 | 2019-2025 | Trintellix |
| Horizon Therapeutics Plc | $127.68 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlin Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.